419 related articles for article (PubMed ID: 26224587)
1. Cinacalcet therapy in patients affected by primary hyperparathyroidism associated to Multiple Endocrine Neoplasia Syndrome type 1 (MEN1).
Giusti F; Cianferotti L; Gronchi G; Cioppi F; Masi L; Faggiano A; Colao A; Ferolla P; Brandi ML
Endocrine; 2016 Jun; 52(3):495-506. PubMed ID: 26224587
[TBL] [Abstract][Full Text] [Related]
2. MEN1-related hyperparathyroidism: response to cinacalcet and its relationship with the calcium-sensing receptor gene variant Arg990Gly.
Filopanti M; Verga U; Ermetici F; Olgiati L; Eller-Vainicher C; Corbetta S; Persani L; Beck-Peccoz P; Spada A
Eur J Endocrinol; 2012 Aug; 167(2):157-64. PubMed ID: 22577108
[TBL] [Abstract][Full Text] [Related]
3. Impact of cinacalcet hydrochloride in clinical management of primary hyperparathyroidism in multiple endocrine neoplasia type 1.
Del Prete M; Marotta V; Ramundo V; Marciello F; Di Sarno A; Esposito R; Carratù AC; De Luca Di Roseto C; Di Somma C; Colao A; Faggiano A
Minerva Endocrinol; 2013 Dec; 38(4):389-94. PubMed ID: 24285106
[TBL] [Abstract][Full Text] [Related]
4. Reduction in parathyroid adenomas by cinacalcet therapy in patients with primary hyperparathyroidism.
Minezaki M; Takashi Y; Ochi K; Mitsuoka R; Yamao Y; Kudo T; Kawanami D; Kobayashi K; Abe I
J Bone Miner Metab; 2021 Jul; 39(4):583-588. PubMed ID: 33409573
[TBL] [Abstract][Full Text] [Related]
5. A patient with MEN1-associated hyperparathyroidism, responsive to cinacalcet.
Falchetti A; Cilotti A; Vaggelli L; Masi L; Amedei A; Cioppi F; Tonelli F; Brandi ML
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):351-7. PubMed ID: 18414463
[TBL] [Abstract][Full Text] [Related]
6. Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism.
Takeuchi Y; Takahashi S; Miura D; Katagiri M; Nakashima N; Ohishi H; Shimazaki R; Tominaga Y
J Bone Miner Metab; 2017 Nov; 35(6):616-622. PubMed ID: 27873072
[TBL] [Abstract][Full Text] [Related]
7. Cinacalcet hydrochloride reduces the serum calcium concentration in inoperable parathyroid carcinoma.
Silverberg SJ; Rubin MR; Faiman C; Peacock M; Shoback DM; Smallridge RC; Schwanauer LE; Olson KA; Klassen P; Bilezikian JP
J Clin Endocrinol Metab; 2007 Oct; 92(10):3803-8. PubMed ID: 17666472
[TBL] [Abstract][Full Text] [Related]
8. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
Dong BJ
Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
[TBL] [Abstract][Full Text] [Related]
9. Bone and Mineral Metabolism Phenotypes in MEN1-Related and Sporadic Primary Hyperparathyroidism, before and after Parathyroidectomy.
Marini F; Giusti F; Cioppi F; Maraghelli D; Cavalli T; Tonelli F; Brandi ML
Cells; 2021 Jul; 10(8):. PubMed ID: 34440663
[TBL] [Abstract][Full Text] [Related]
10. The role of calcimimetics in the treatment of hyperparathyroidism.
Wüthrich RP; Martin D; Bilezikian JP
Eur J Clin Invest; 2007 Dec; 37(12):915-22. PubMed ID: 18036025
[TBL] [Abstract][Full Text] [Related]
11. Hypercalcemia of primary hyperparathyroidism was treated by cinacalcet in a patient with liver cirrhosis.
Akinci B; Comlekci A; Tankurt E
Exp Clin Endocrinol Diabetes; 2009 Mar; 117(3):142-5. PubMed ID: 18561096
[TBL] [Abstract][Full Text] [Related]
12. Reoperative Surgery in Patients with Multiple Endocrine Neoplasia Type 1 Associated Primary Hyperparathyroidism.
Keutgen XM; Nilubol N; Agarwal S; Welch J; Cochran C; Marx SJ; Weinstein LS; Simonds WF; Kebebew E
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):701-707. PubMed ID: 27464610
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Persistent Hypercalcemia and Hyperparathyroidism With Cinacalcet After Successful Kidney Transplantation.
Ważna-Jabłońska E; Gałązka Z; Durlik M
Transplant Proc; 2016 Jun; 48(5):1623-5. PubMed ID: 27496458
[TBL] [Abstract][Full Text] [Related]
14. Effect of treatment with depot somatostatin analogue octreotide on primary hyperparathyroidism (PHP) in multiple endocrine neoplasia type 1 (MEN1) patients.
Faggiano A; Tavares LB; Tauchmanova L; Milone F; Mansueto G; Ramundo V; De Caro ML; Lombardi G; De Rosa G; Colao A
Clin Endocrinol (Oxf); 2008 Nov; 69(5):756-62. PubMed ID: 18485119
[TBL] [Abstract][Full Text] [Related]
15. [Cinacalcet--a new drug for the treatment of secondary hyperparathyroidism in patients with uraemia, parathyroid cancer or primary hyperparathyroidism].
Vestergaard P; Nielsen LR; Mosekilde L
Ugeskr Laeger; 2006 Jan; 168(1):29-32. PubMed ID: 16393559
[TBL] [Abstract][Full Text] [Related]
16. Primary hyperparathyroidism in patients with multiple endocrine neoplasia type 1: comparison with sporadic parathyroid adenomas.
Katai M; Sakurai A; Ikeo Y; Hashizume K
Horm Metab Res; 2001 Aug; 33(8):499-503. PubMed ID: 11544565
[TBL] [Abstract][Full Text] [Related]
17. Cinacalcet efficacy in patients with moderately severe primary hyperparathyroidism according to the European Medicine Agency prescription labeling.
Cetani F; Saponaro F; Banti C; Cianferotti L; Vignali E; Chiavistelli S; Viccica G; Pinchera A; Marcocci C
J Endocrinol Invest; 2012 Jul; 35(7):655-60. PubMed ID: 21971564
[TBL] [Abstract][Full Text] [Related]
18. Acute and one-year effects of cinacalcet in patients with persistent primary hyperparathyroidism after unsuccessful parathyroidectomy.
Iglesias P; Ais G; González A; Tajada P; García Arévalo C; Fernández Pardo E; Díez JJ
Am J Med Sci; 2008 Feb; 335(2):111-4. PubMed ID: 18277118
[TBL] [Abstract][Full Text] [Related]
19. [Therapeutic agents for disorders of bone and calcium metabolism. The calcimimetic cinacalcet HCl].
Nakanishi S; Fukagawa M
Clin Calcium; 2007 Jan; 17(1):88-92. PubMed ID: 17211098
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
